File Download

There are no files associated with this item.

Supplementary

Conference Paper: Gut microbiota predicts treatment response to empagliflozin among metabolic dysfunction-associated steatotic liver disease (MASLD) patients without diabetes mellitus.

TitleGut microbiota predicts treatment response to empagliflozin among metabolic dysfunction-associated steatotic liver disease (MASLD) patients without diabetes mellitus.
Authors
Cheung, Ka Shing Michael
Issue Date5-May-2025
Persistent Identifierhttp://hdl.handle.net/10722/355762

 

DC FieldValueLanguage
dc.contributor.authorCheung, Ka Shing Michael-
dc.date.accessioned2025-05-12T00:35:08Z-
dc.date.available2025-05-12T00:35:08Z-
dc.date.issued2025-05-05-
dc.identifier.urihttp://hdl.handle.net/10722/355762-
dc.languageeng-
dc.relation.ispartofDigestive Disease Week (03/05/2025-06/05/2025, San Diego)-
dc.titleGut microbiota predicts treatment response to empagliflozin among metabolic dysfunction-associated steatotic liver disease (MASLD) patients without diabetes mellitus.-
dc.typeConference_Paper-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats